Oblenio Bio
Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through our LBL-051 T-cell engager.
$62M Series B+ ·
Led by Pfizer Venture Investments · Source: fundraisingfox.com
Funding history ↓Signals
Website registeredNov 28, 2023 (3 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | $62M | fundraisingfox.com |
Timeline
- Website created
Investors
Companies like Oblenio Bio
AAnaveon$120M Series B+ · Dec 2021
FFlip TherapeuticsSeed · Sep 2026
RRheumaGenSeries A · Dec 2025
CCatalYm$150M Series B+ · Jul 2024
OOuro Medicines$120M Series A · Jan 2025
CCoultreon$125M Series A · Apr 2026
Other companies backed by Pfizer Venture Investments
DDren Bio$350M Series B+ · Oct 2026VVedanta Biosciences$60M Series B+ · Aug 2026
FFlare Therapeutics$85M Series B+ · Jun 2026
TTRIMTECH Therapeutics$14M Seed · Jun 2026
CCellCentric$220M Series B+ · May 2026
SStorm Therapeutics$56M Series B+ · Apr 2026
Pfizer Venture Investments portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/oblenio-bio (get a free API key).